Онкогематология (Nov 2022)

Epstein–Barr virus infection in patients after hematopoietic stem cells transplantation

  • D. N. Balashov,
  • L. N. Shelikhova,
  • A. A. Demushkina,
  • P. E. Trakhtman,
  • Ye. V. Skorobogatova,
  • D. V. Litvinov,
  • Ye. V. Raykina,
  • A. A. Maschan

Journal volume & issue
Vol. 0, no. 3
pp. 59 – 64

Abstract

Read online

Epstein–Barr virus (EBV) is a member of herpes-viruses family. Now it is well-known, that it can be a cause of wide spectrum lymphoproliferative disoders. The given problem is especially serious after hematopoietic stem cells transplantation (HSCT); frequency of death linked to this complication can achieve 50–90 %. Risk factors for development of posttransplant lymphoproliferative syndromes (PTLS) are: using partially compatible graft, T-cell depletion, presence of severe acute graft-versus-host reaction (GVHD), using of antitymocytic globulin, etc. Severity of associated with EBV posttransplant complications and problems relate to absence of clear diagnostic algorithm, PTLS prophylactic and therapy schedule are argument for necessity of the further studies.

Keywords